Overview

Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Buprenorphine
Cannabidiol
Epidiolex
Criteria
Inclusion Criteria:

- Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) opioid use
disorder, severe

- Currently in treatment with methadone or buprenorphine

Exclusion Criteria:

- Requiring level of care higher than outpatient treatment for alcohol,
sedative/hypnotics, or stimulants

- Any current mood episode requiring level of care higher than outpatient treatment

- History of psychotic disorder or bipolar disorder

- Currently pregnant

- Hepatic liver enzymes greater than 3x upper normal limit

- Hypersensitivity to cannabinoids or sesame oil (cannabidiol solution comes in sesame
oil emulsion)

- Currently taking any medications with known significant pharmacokinetic interactions
with CBD